A Multicenter, Randomized, Double-blind, Prospective Study to Evaluate the Efficacy and Safety of Vincristine, Dactinomycin/Cyclophosphamide Combination Therapy Combined With Liposomal Doxorubicin/Doxorubicin/Pharmorubicin/Pirarubicin in 0.5-14 Year Old Children With Nephroblastoma.

This study aims to estimate the efficacy and side effects of study drugs in children with nephroblastoma who are treated with combination therapy.

开始日期2019-06-01

申办/合作机构

ShengJing Hospital

IRCT201112208472N1 / Completed早期临床1期IIT

Evaluation of the effect of Oxytetracycline Spray in treatment of diabetic foot ulcers

开始日期2010-03-21

申办/合作机构

Mashhad University of Medical Sciences

100 项与土霉素相关的临床结果

登录后查看更多信息

100 项与土霉素相关的转化医学

登录后查看更多信息

100 项与土霉素相关的专利（医药）

登录后查看更多信息

7,163

项与土霉素相关的文献（医药）

2025-02-01·FOOD CHEMISTRY

A smartphone-integrated bimetallic ratiometric fluorescent probe for specific visual detection of tetracycline antibiotics in food samples and latent fingerprinting

Article

作者: Chen, Jiang-Hai ; Sun, Yu ; Ji, Bo-Tao ; Zhao, Biao ; Li, Jin-Guo ; Sun, Yin-Xia ; Gao, Lu-Lu ; Liu, Li-Ping ; Deng, Zhe-Peng ; Wang, Jian-Jun

Designing and preparing highly sensitive and accurate fluorescent chemosensors for monitoring tetracycline antibiotics remains a challenge. Herein, a fluorescent chemosensor based on lanthanide metal-organic frameworks (Ln-MOFs) is proposed to realize high-precision monitoring by adjusting the ratio of lanthanide ions. Ln-MOFs with good aqueous stability were prepared by a solvothermal method using Eu³⁺, Tb³⁺ and the ligand 4,4',4″-s-triazine-2,4,6-triyltribenzoic acid (H₃TATB) in DMF/NMP/H₂O. The Ln-MOFs could recognize oxytetracycline (OTC) and doxycycline (DOX), and the detection limits of OTC and DOX were as low as 8.6 and 4.8 nM, respectively. In particular, Eu_{(1.4 μM)}-Tb-MOF sensors were used for visual detection of OTC and DOX in combination with smartphones with detection lines as low as 9.8 nM and 14.2 nM, respectively. Meanwhile, Eu-MOF, Tb-MOF and Eu_{(1.4 μM)}-Tb-MOF can be used for latent fingerprint (LFP) visualization, demonstrating their potential applications in the field of criminal case investigation. The developed probes were successfully applied to determining OTC and DOX in milk, beef and pork with recoveries ranging from 92.0 % to 109.63 % and relative standard deviations (RSDs) ranging from 1.83 % to 4.56 %. Eu_{(1.4 μM)}-Tb-MOF is believed to utilize its lanthanide metal ion coordination and photoinduced electron transfer (PET) mechanism to achieve highly selective and accurate OTC and DOX detection, which is supported by experimental and density functional theory (DFT) calculations.

2025-02-01·JOURNAL OF COLLOID AND INTERFACE SCIENCE

Specific smart sensing of electron-rich antibiotics or histidine improves the antenna effect, luminescence, and photodynamic sterilization capabilities of lanthanide polyoxometalates

Article

作者: Liang, Fu-Pei ; Zhu, Zhong-Hong ; Tang, Meng-Juan ; Li, Yun-Lan ; Zou, Hua-Hong ; Wang, Hai-Ling ; Qin, Wen-Wen

Excessive discharge of antibiotics seriously threatens human health and is thus a global public health problem. This highlights the urgent need to develop intelligent sensing materials for specific antibiotics that are highly visual, fast, convenient, and inexpensive. Herein, two reverse α-octamolybdate polyoxometalates (POMs; Mo₈) were used to chelate lanthanide ions to obtain lanthanide POMs (LnPOMs; LnMo₁₆; Ln = Eu, Sm, Tb, Gd) with highly sensitive smart photoresponses to specific antibiotics (ofloxacin [OFN], norfloxacin [NOR], enrofloxacin [ENR], and oxytetracycline [OTC]) and histidine (His) with luminescence turn-on. Specific antibiotics and His, which has an electron-rich structure, can efficiently enhance the antenna effect, thereby greatly improving the luminescence of EuMo₁₆. Surprisingly, OFN and NOR both enhanced the luminescence of Eu(III) ions and Mo₈, whereas ENR and OTC only enhanced the luminescence of Eu(III) ions, showing a differentiated sensitization effect. More notably, the combination of POMs and Ln(III) ions enhanced the ability of LnPOMs to produce reactive oxygen species under light irradiation, and these LnPOMs showed significant sterilization effects on Escherichia coli and Staphylococcus aureus. To our knowledge, this is the first time electron-rich antibiotics or amino acids were used to enhance the luminescence of LnPOMs, achieving luminescence-enhanced photoresponse to specific antibiotics and amino acids.

2025-02-01·NEUROCHEMICAL RESEARCH

Oxytocin Protects Against Corticosterone-Induced DA Dysfunction: An Involvement of the PKA/CREB Pathway

Article

作者: Sookkua, Tichaporn ; Chaipunko, Sirinun ; Nopparat, Chutikorn ; Chutabhakdikul, Nuanchan

Abstract:

Chronic stress disrupts dopamine (DA) transmission, adversely affecting mood and contribution to neuropsychiatric disorders like ADHD, autism, schizophrenia, anxiety, depression, and drug addiction. The neuropeptide oxytocin (OXT) plays a key role in social cognition, bonding, attachment, and parenting behaviors. In addition, OXT can modulate the activity of the HPA axis, counteracting the effects of stress, and alleviating fear and anxiety. However, whether OXT can mitigate stress-induced DA dysfunction and the underlying mechanisms remains unclear. This study investigated the neuroprotective effects of OXT on corticosterone (CORT) induced DA dysfunction in the neuroblastoma cell line SH-SY5Y. The results revealed that CORT decreases the levels of intracellular signaling molecules associated with DA function, including phosphorylated tyrosine hydroxylase (pTH), phosphorylated cAMP response element-binding protein (pCREB), and protein kinase A (PKA). Interestingly, pretreatment with OXT mitigated CORT-induced DA dysfunction through its potent PKA activator properties. In addition, the neuroprotective effect of OXT was abolished by atosiban (an OXT receptor antagonist) or H89 (a PKA inhibitor). Our results suggest that OXT protects dopaminergic neuroblastoma cells from CORT-induced DA dysfunction, potentially through the involvement of oxytocin receptors and the PKA/CREB signaling pathway. These findings contribute to the understanding of the neurobiological mechanisms underlying stress resilience and highlight potential pathways for developing targeted treatments that leverage the neuroprotective properties of OXT to address disorders characterized by DA dysregulation and impaired stress responses.

项与土霉素相关的新闻（医药）

2024-10-29

·药智网

“宇宙药厂”转折点来了？

生物医药行业总是风云变幻。 2022年，辉瑞公司年收入突破千亿美元，成为全球营收最多的制药企业。然而，随着新冠疫情迅速退潮，2023年营收下降了41%，营收排名也从第一跌到了第四。近日，著名的激进投资机构Starboard value携10亿美元入股辉瑞，将给这家制药巨头带来怎样的改变？ 01 千亿美元大厂 1849年，Charles Pfizer和Charles Erhart在纽约创立了辉瑞公司，最初以生产化工产品为主。二战期间，辉瑞成功量产青霉素，又推出了土霉素，正式进军制药行业。此后，辉瑞通过研发和并购不断扩张，推出了如络活喜、万艾可等重磅药物，并逐渐成为全球领先的制药企业。进入21世纪以来，辉瑞从2001年到2013年连续蝉联全球制药企业50强（Pharm Exec Top50）榜首，被称为“宇宙药厂”。 2020年，COVID-19新冠病毒席卷全球，辉瑞与BioNTech合作，迅速推出了mRNA COVID-19疫苗Comirnaty，又自主开发了新冠口服药物Paxlovid。图片来源：参考资料凭借这两款新冠产品的畅销，2021年辉瑞销售收入达到720.43亿美元，2022年辉瑞公司的收入更是突破了千亿美元，达到了1003亿美元，创下了公司174年历史上的最高纪录。其中COVID-19疫苗Comirnaty在2022年的销售额为378亿美元，新冠口服药物Paxlovid在2022年的销售额为189亿美元，新冠相关产品收入合计567亿美元。但是，疫情很快发生了变化，2023年新冠产品的销售额并没有如辉瑞预计的那样继续畅销。 2023年，Comirnaty和Paxlovid合计销售额125亿美元，远低于辉瑞管理层预计的215亿美元。而2024年，这两款产品的继续大幅下降，没有实现辉瑞预期额增长。或许是新冠疫情变化太快，辉瑞应对不足，导致营收大幅下降，2023年全年收入585亿美元，同比下降41%。资本市场上，辉瑞目前股价不到30美元，比2021年12月高点的近60美元，降低了50%，甚至略低于疫情前的水平。 02 质疑声起近日，Starboard准备了一份关于辉瑞的投资者峰会演示文稿，讨论了辉瑞的市场表现、研发管线、以及并购投资等。首先，他肯定了辉瑞在新冠疫情中做出的贡献，但他认为，辉瑞的之后表现落后于同行和市场，包括研发管线不及预期、巨额并购没有带来预期的回报等。在研发方面，辉瑞曾在2018年定下未来5年内推出15个“重磅炸弹”的目标，然而回看这些管线，辉瑞遇到了不少挑战。图片来源：参考资料过去几年，辉瑞除了在新冠产品上的成功，还推出了不少创新药，例如： Vyndaqel(tafamidis meglumine)是辉瑞开发的一款口服TTR稳定剂，于2019年获得美国FDA批准，是首个也是唯一一个治疗ATTR-CM的药物。2023年Vyndaqel系列药物销售额为33.2亿美元，今年上半年该药销售额24.6亿美元，同比增长68%。 PCV20（Prevnar 20，20价肺炎球菌结合疫苗）成功接替了PCV13，成为辉瑞业绩的一大亮点。 RSV疫苗Abrysvo在2023年5月获批后，首年即产生了8.9亿美元的收入。但是，不达预期的项目也有很多。例如，Bavencio虽已获得监管机构批准上市，但距离“重磅炸弹”门槛（10亿美元）还尚远。而且辉瑞在2023年3月终止了与默克的合作，并将相关权益转交给默克。Cibinqo(JAK1)、Litfulo(JAK3)两款自免新药放量也较慢。另外，C.Difficile疫苗、Rivipansel、Tanezumab等新药未能顺利获批上市，而且其重磅乳腺癌药Ibrance一项III期研究结果不佳。而在热门领域，Bourla将GLP-1项目视为潜在的100亿美元产品。但由于安全性等问题，辉瑞终止了第二代小分子GLP-1R药物lotiglipron(PF-07081532)的开发。Danuglipron（每日口服两次）也因为副作用导致的高退出率。而后，辉瑞又推出了每日口服一次的改良版danuglipron，目前其用于治疗型糖尿病和肥胖两个适应症均处于临床Ⅰ期。另一款口服小分子GLP-RA药物PF-06954522也还处于临床Ⅰ期，进度落后于竞争对手。在并购方面，辉瑞在新冠产品获得充沛现金流后，其“巨额并购”的基因觉醒，斥资430亿美元收购ADC公司Seagen。疫情以来，辉瑞用于并购的资金更是高达700亿美元。表1 辉瑞的部分巨额并购数据来源：辉瑞官网以及公开信息整理但是，这些并购没能带来预期中的回报。Seagen在2024年上半年，为辉瑞带来了15.87亿美元的收入。但这与辉瑞此前预测的“到2030年，Seagen系列产品有望贡献超100亿美元的年销售额”还有不少距离。另外，辉瑞在2022年以54亿美元的价格收购Global Blood Therapeutics，获得了镰状细胞病药物Oxbryta（voxelotor）。但近日，出于对患者最佳利益考虑，辉瑞从全球市场撤回了这款药物。祸不单行，2022年辉瑞以5.25亿美元收购ReViral，获得的两个RSV候选药物Sisunatovir和RV-299（RSV N蛋白抑制剂）也相继被辉瑞从管线中剔除。 03 转折将至？辉瑞无论是自研，还是外部引进的管线似乎都遇到了不小挑战。而新冠疫情又变化太快，辉瑞新冠产品没能给公司带来预期的收入，针对辉瑞的质疑声越来越多。此时，Starboard value携10亿美元入股辉瑞，虽然其股票占辉瑞总市值不到1%，但其可以通过各种方式说服其他股东加入自己的阵线，迫使管理层调整策略。据悉，Starboard Value由杰夫·史密斯（Jeff Smith）创立，风格强势，是华尔街最令人“畏惧”的激进投资机构之一。其通常的投资策略是，持有公司部分股权，力图对公司管理层和董事会施压，推动公司进行战略调整、削减成本、推动并购和改革，以优化运营效率，提升价值，为股东带来更高回报。这一次，Starboard Value问责辉瑞，指出导致其市值下跌的一系列原因，包括内部研发不顺利、管线估值低、巨额并购回报有限、未能达到预期的业务目标等问题，并敦促辉瑞降本提效，调整策略。实际上，辉瑞早已开始调整，2023年辉瑞宣布削减40亿美元开支的计划，今年5月又公布了一项新计划，到2027年底再削减15亿美元开支。基于这两项计划，辉瑞在去年和今年都进行了多次裁员。在人事上，辉瑞也频繁调整，聘请了前诺华美国肿瘤业务的高级副总裁Tina Deignan担任肿瘤学商业化负责人，以帮助公司实现到2030年销售8种重磅药物的目标。另外，辉瑞首席科学官兼研发总裁Mikael Dolsten博士也将离职，辉瑞正在寻找研发部门的下一任负责人。无论是否受制于Starboard Value的压力，辉瑞都已开始改变，相信在不久的将来，我们将看到这家制药巨头的新面貌。参考来源： 1.https://www.fiercepharma.com/pharma/starboard-wants-hold-pfizer-leadership-accountable-overpaid-ma-deals-poor-return-rd 2.https://www.pfizer.com/news/press-release/press-release-detail/tim-buckley-elected-pfizers-board-directors 3.辉瑞：2024 Active-Passive Investor Summit 声明：本内容仅用作医药行业信息传播，为作者独立观点，不代表药智网立场。如需转载，请务必注明文章作者和来源。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑 | 小月石转载开白 | 马老师 18996384680（同微信）商务合作 | 王存星 19922864877（同微信）阅读原文，是受欢迎的文章哦

疫苗并购信使RNA财报紧急使用授权

2024-07-12

·PRNewswire

Qilian International Holding Group Ltd Regained Compliance with Nasdaq's Minimum Bid Price Rule

CHENGDU, China, July 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that on July 10, 2024, NASDAQ notified the Company that it has determined that for the 10 consecutive business days, from June 21, 2024 to July 9, 2024, the closing bid price of the Company's Class A ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and NASDAQ has closed this matter. About Qilian International Holding Group Ltd Qilian International Holding Group Ltd, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Company's products are sold in more than 20 provinces in China. For more information, visit the Company's website at . Safe Harbor Statement Certain statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, are: the ability to manage growth; ability to identify and integrate other future acquisitions; ability to obtain additional financing in the future to fund capital expenditures; fluctuations in general economic and business conditions; costs or other factors adversely affecting our profitability; litigation involving patents, intellectual property, and other matters; potential changes in the legislative and regulatory environment; a pandemic or epidemic. The forward-looking statements contained in this release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission, which are available for review at . The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Such information speaks only as of the date of this release. SOURCE Qilian International Holding Group Limited

2024-05-17

·PRNewswire

Qilian International plans to adjust industrial investment

JIUQUAN, China, May 17, 2024 /PRNewswire/ -- Qilian International Holdings Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), a pharmaceutical and chemical products manufacturer headquartered in China, today announced: In the past two years, Qilian International Holdings Group Limited has encountered significant challenges stemming from the continuous shrinkage in market demand for its oxytetracycline products, coupled with a persistent decline in market prices and escalating environmental protection standards. These factors have collectively led to a substantial increase in the production and operational costs for Qilian International, consequently impairing the profitability of the oxytetracycline industry. In response to these challenges and in an effort to optimize resource allocation and enhance the company's overall efficiency, Qilian International is planning to reorient its industrial strategy in accordance with the prevailing market conditions and its long-term development objectives. Firstly, Qilian International will reduce its investment in the oxytetracycline sector. The company plans to substantially decrease its capital allocation to the oxytetracycline industry, aiming to mitigate production and operational costs as well as to manage business risks more effectively. Secondly, the company intends to bolster its investment in the heparin sodium sector. Recognized for its critical role as a biomedical raw material, heparin sodium offers extensive application prospects and a promising market outlook within the medical field. Qilian International is committed to significantly enhancing its investment in the research and development, production, and market development of heparin sodium. This strategic move is designed to refine the production techniques and expand the scale of heparin sodium production, thereby addressing the escalating market demands. Thirdly, the company plans to develop a series of licorice products. Qilian International will closely monitor market trends and augment its investment in the research, production, and marketing of licorice-based products, including licorice extract, fluid extract, and compound licorice lozenges. This strategic expansion is intended to broaden the company's market share and enhance profitability. The fourth is to invest in the financial field (stocks, wealth management, etc.) and software development. With the rapid development of financial technology, the development of financial products and software in the financial field has become a new growth point. The company will actively seize the opportunity to invest appropriately in financial products in the financial field, and gradually increase investment in software development to promote the diversified development of the company. Adjusting its industrial orientation is a key initiative for the company to proactively adapt to market changes and optimize resource allocation. In the future, through the implementation of the adjustment plan, the company will continue to innovate the business concept, further enhance the overall competitiveness and profitability, promote the sustainable and healthy development of the company, and create greater value for the majority of shareholders and partners. About Qilian International Holding Group Ltd Qilian International Holding Group Limited, headquartered in Gansu, is a leading manufacturer of pharmaceutical and chemical products in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Company's products are sold in more than 20 provinces in China. For more information, visit the Company's website at Safe Harbor Statement Certain statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, are: the ability to manage growth; ability to identify and integrate other future acquisitions; ability to obtain additional financing in the future to fund capital expenditures; fluctuations in general economic and business conditions; costs or other factors adversely affecting our profitability; litigation involving patents, intellectual property, and other matters; potential changes in the legislative and regulatory environment; a pandemic or epidemic. The forward-looking statements contained in this release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission, which are available for review at . The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Such information speaks only as of the date of this release. For more information, please visit our website. Media contact: JIANG YUBIN [email protected] [email protected] SOURCE Qilian International Holding Group Limited

100 项与土霉素相关的药物交易

登录后查看更多信息